SELLAS Life Sciences GroupSLS +12.44%25 PB Ratio is 17.41 as of Jun. 25, 2026, which is 215% above its 10-year median of 5.52. GuruFocus rates SLS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, SELLAS Life Sciences Group ranks worse than 91.48% on this metric.
The historical rank and industry rank for SELLAS Life Sciences Group's PB Ratio or its related term are showing as below:
SLS'
s PB Ratio Range Over the Past 10 Years
Min: 2.19 Med: 5.52 Max: 40.26
Current: 17.47
During the past 13 years, SELLAS Life Sciences Group's highest PB Ratio was 40.26. The lowest was 2.19. And the median was 5.52.
SLS's PB Ratio is ranked worse than 91.48% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs SLS: 17.47
During the past 12 months, SELLAS Life Sciences Group's average Book Value Per Share Growth Rate was 94.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 26.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of SELLAS Life Sciences Group was 132.00% per year. The lowest was -87.50% per year. And the median was -42.20% per year.
Back to Basics: PB Ratio
SELLAS Life Sciences Group (NAS:SLS) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
SELLAS Life Sciences Group PB Ratio Related Terms
SELLAS Life Sciences Group PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SELLAS Life Sciences Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
SELLAS Life Sciences Group (SLS) has a PB Ratio of 17.41 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SELLAS Life Sciences Group and its competitors. This is 215% above median its historical median of 5.52. Over the past decade, SELLAS Life Sciences Group's PB Ratio has ranged from 2.19 to 40.26. According to the industry distribution chart, SELLAS Life Sciences Group ranks #1128 out of 1233 companies in the Biotechnology industry, placing it in the top 91.5%.
Is SELLAS Life Sciences Group's PB Ratio too high?
SELLAS Life Sciences Group's current PB Ratio of 17.41 is 215% above median its 10-year median of 5.52. Over the past 10 years, this metric has ranged from a low of 2.19 to a high of 40.26. The Biotechnology industry median PB Ratio is 2.80. SELLAS Life Sciences Group's value of 17.41 is 521.8% above this industry median. Based on the distribution chart, SELLAS Life Sciences Group ranks #1128 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's PB Ratio compare to SNDX and CAPR?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #1128 out of 1233 companies for PB Ratio. This places SELLAS Life Sciences Group in the lower half of its industry. The industry median PB Ratio is 2.80. SELLAS Life Sciences Group's value of 17.41 is 521.8% above this benchmark. Historically, SELLAS Life Sciences Group's own PB Ratio has ranged from 2.19 to 40.26 over the past decade. While the company's 10-year median is 5.52 vs. the industry median of 2.80, SELLAS Life Sciences Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SELLAS Life Sciences Group's current PB Ratio of 17.41 is 521.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current PB Ratio is 17.41, which is 215% above median its own 10-year median of 5.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current PB Ratio of 17.41. The current PB Ratio is 17.41, which is 215% above median its 10-year median of 5.52 and 521.8% above the Biotechnology industry median of 2.80. SELLAS Life Sciences Group's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current PB Ratio is 17.41 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score
Get the complete analysis for SLS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
